3,5-dimethyl-4-(dimethylamino)benzaldehyde | 76166-10-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,5-dimethyl-4-(dimethylamino)benzaldehyde
• 英文别名: 4-(Dimethylamino)-3,5-dimethylbenzaldehyde
• CAS: 76166-10-4
• 化学式: C₁₁H₁₅NO
• 分子量: 177.246
• InChiKey: TZLWLXBWPJXPEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,5-dimethyl-4-(dimethylamino)benzaldehyde 在 盐酸羟胺 、 水 、 potassium carbonate 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以21%的产率得到4-Dimethylamino-3,5-dimethyl-benzaldehyde oxime
  参考文献：
  名称：

  EFFICIENCY OF THE VILSMEIER-HAACK METHOD IN THE SYNTHESIS OFp-AMINOBENZALDEHYDES

  摘要：

  DOI：

  10.1080/00304949809355310
• 作为产物：
  描述：

  乌洛托品 、 2,6,N,N-四甲基苯胺 在 聚合甲醛 、 溶剂黄146 作用下， 以24%的产率得到3,5-dimethyl-4-(dimethylamino)benzaldehyde
  参考文献：
  名称：

  EFFICIENCY OF THE VILSMEIER-HAACK METHOD IN THE SYNTHESIS OFp-AMINOBENZALDEHYDES

  摘要：

  DOI：

  10.1080/00304949809355310

文献信息

• 3-Alkyl-2-aryl-3H-naphth[1,2-d]imidazoles, a novel class of nonacidic antiinflammatory agents
  作者：Emilio Toja、Domenica Selva、Pierfranco Schiatti

  DOI：10.1021/jm00371a010

  日期：1984.5

  Novel 3-alkyl-2-aryl-3H- naphth [1,2-d]imidazoles were synthesized and evaluated as antiinflammatory agents in the carrageenin-induced paw edema, cotton pellet induced granuloma, and adjuvant-induced polyarthritis assays in rats. The analgesic, antipyretic, and gastroulcerogenic effects were also tested. Structure-activity relationships are discussed. One of the compounds, 3-(1-methylethyl)-2-(4-methoxyphenyl)-3H-

  合成了新型的3-烷基-2-芳基-3H-萘[1,2-d]咪唑类，并在角叉菜胶诱发的爪水肿，棉丸诱发的肉芽肿和佐剂诱发的多关节炎试验中用作抗炎药。还测试了止痛，解热和胃溃疡的作用。讨论了构效关系。选择一种化合物3-（1-甲基乙基）-2-（4-甲氧基苯基）-3H-萘并[1,2-d]咪唑（35）作为非酸性抗炎和镇痛药进行临床试验。
• Photochemische Synthesen potentiell hypoglykämisch wirkender 3-Oxazoline
  作者：Karl-Heinz Pfoertner、Karl Bernauer、Franz Kaufmann、Eckehard Lorch

  DOI：10.1002/hlca.19850680308

  日期：1985.5.15

  Photochemical Syntheses of 3-Oxazolines which Possibly Exhibit Hypoglycemic Activity

  3-恶唑啉的光化学合成可能表现出降血糖活性
• Oxazolines
  申请人：Hoffmann-La Roche Inc.

  公开号：US04317914A1

  公开（公告）日：1982-03-02

  Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen or C.sub.1-3 alkyl; R.sup.8 is hydrogen, lower alkyl or formyl; R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl; and n is 0 (zero) or, when both R.sup.7 and R.sup.8 are lower alkyl, n is 0 (zero) or 1, prepared, inter alia, from p-aminobenzaldehydes which may be N-alkyl substituted, are described. The compounds of formula I are orally active antidiabetic agents.

  式##STR1##的化合物，其中R.sup.1和R.sup.2独立地为氢、卤素或较低的烷基；R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7独立地为氢或C.sub.1-3烷基；R.sup.8为氢、较低的烷基或甲酰基；R.sup.9和R.sup.10独立地为甲基或三氟甲基；n为0（零）或当R.sup.7和R.sup.8都为较低的烷基时，n为0（零）或1，从可能被N-烷基取代的对氨基苯甲醛等制备而得。式I的化合物是口服活性抗糖尿病药物。
• Development of fluorescence probes based on stilbazolium salts for monitoring free radical polymerization processes
  作者：Stanisław Wróblewski、Katarzyna Trzebiatowska、Beata Jędrzejewska、Marek Pietrzak、Ryszard Gawinecki、Jerzy Pączkowski

  DOI：10.1039/a902904d

  日期：——

  A series of 1-methyl-2-(4-aminostyryl)pyridinium perchlorates and iodides were investigated as fluorescent probes for the monitoring of the progress of free radical polymerization. The study on the changes in the fluorescence intensity and spectroscopic shifts of studied compounds were carried out during thermally initiated polymerization of methyl methacrylate and during photoinitiated polymerization of a 2-ethyl-2-(hydroxymethyl)propane-1,3-diol triacrylate (TMPTA)–1-methylpyrrolidin-2-one (MP) mixture. The purpose of these studies was to find a relationship between the changes in the shape and intensity of probe fluorescence and degree of monomer conversion into polymer. The polymer formation was estimated gravimetrically or by the measurement of the degree of monomer double bond disappearance using FTIR spectroscopy.

  研究人员将一系列 1-甲基-2-(4-氨基苯乙烯基)吡啶高氯酸盐和碘化物作为监测自由基聚合过程的荧光探针。在甲基丙烯酸甲酯的热引发聚合和 2-乙基-2-（羟甲基）丙烷-1,3-二醇三丙烯酸酯（TMPTA）-1-甲基吡咯烷-2-酮（MP）混合物的光引发聚合过程中，对所研究化合物的荧光强度变化和光谱偏移进行了研究。这些研究的目的是找出探针荧光的形状和强度变化与单体转化为聚合物的程度之间的关系。聚合物的形成可用重力法或傅立叶变换红外光谱法测量单体双键消失的程度来估算。
• 5-[p-(Substituted)phenyl]-2,2-dialkyl-4-phenyl-3-oxazoline
  申请人：Hoffmann-La Roche Inc.

  公开号：US04360530A1

  公开（公告）日：1982-11-23

  Compounds of the formula ##STR1## wherein R.sup.1 and R.sup.2, independently, are hydrogen, halogen or lower alkyl; R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7, independently, are hydrogen or lower alkyl; R.sup.8 is hydrogen, lower alkyl or formyl; R.sup.9 and R.sup.10, independently, are methyl or trifluoromethyl; and n is 0 (zero) or, when both R.sup.7 and R.sup.8 are lower alkyl, n is 0 (zero) or 1, prepared, inter alia, from p-aminobenzaldehydes which may be N-alkyl substituted, are described. The compounds of formula I are orally active antidiabetic agents.

  化合物的公式为##STR1##其中，R.sup.1和R.sup.2独立地为氢、卤素或较低的烷基；R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7独立地为氢或较低的烷基；R.sup.8为氢、较低的烷基或甲酰基；R.sup.9和R.sup.10独立地为甲基或三氟甲基；当R.sup.7和R.sup.8均为较低的烷基时，n为0（零）或1。其中，化合物可通过p-氨基苯甲醛制备，其可能被N-烷基取代。公式I的化合物是口服活性抗糖尿病药物。